A Phase 3b/4, Open-label Study to Assess the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in Previously Vaccinated Adults Aged ≥18 Years
Latest Information Update: 30 Sep 2024
Price :
$35 *
At a glance
- Drugs Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Moderna Therapeutics
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.
- 10 Sep 2024 New trial record